Document Type
Poster Presentation
Publication Date
12-2024
Department
Pharmacy
Abstract
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and soft tissue infections caused by gram-positive microorganisms.
Used off-label in the management of infective endocarditis in IV drug users, as well as in osteomyelitis infections.
Extremely long half-life of greater than a week.
Potential cost-effective option for susceptible gram-positive infections and increased patient compliance.
Publication Information
Lombardi, Nicholas; Kritikos, Anthoula; Ye, Jacky; and Cohen, Victor, "Dalbavancin Use at a Health System Network in Compliance with a Standard Plan of Treatment for Infective Endocarditis and Osteomyelitis" (2024). Doctoral External Publications. Paper 94.
https://fisherpub.sjf.edu/doctoral_ext_pub/94
Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.
Comments
Poster presented at the ASHP Midyear Clinical Meeting & Exhibition in New Orleans, December 8-12, 2024